News
First living tissue 3D printed in space aboard International Space Station
Using the “Organaut”, a 3D bioprinter designed for microgravity, Russia has become the first country to print living tissue in space. After a December 3rd cargo delivery to the International Space Station (ISS), cosmonaut Oleg Kononenko completed an experiment with the machine in the Russian sector of the station, successfully producing human cartilage tissue and a rodent thyroid gland. The Organaut was designed via a collaboration with the printer’s maker, 3D Bioprinting Solutions, and Russia’s national space agency, Roscosmos. The United States also has its own bioprinting mission scheduled for the first half of 2019, joining in the march to develop biological solutions for problems that space is well suited to solve.
A 3D bioprinter operates by creating one layer at a time of specified tissue or stem cell material arranged as needed to grow and form as biologically programmed to do. As summarized by Aryeh Batt, the CEO of Precise Bio, a company dedicated to 3D printed bioproducts for human eyes, “Essentially, the biology does the work, but you have to put them in the correct environment to make it happen.” In the case of Organaut, an internal robotic mechanism drips living cell fabric layers from an automatic syringe. When living tissue is bioprinted under Earth’s gravity, the artificial cells grow in a flatter structure than their natural state in the human body. In microgravity, however, they form a shape closer to their normal dimensions.
Along with demonstrating the growth advantages of microgravity, Organaut’s tissue samples will provide the ability to study the effect of radiation on the body. “We will look at how the constructs came together, and how they behaved,” confirmed Usef Hesuani, head of laboratory projects and a managing partner of 3D Bioprinting Solutions in a recent press conference. The original Organaut printer was aboard the Soyuz MS-10 spacecraft which experienced an launch failure on October 11, 2018, forcing the U.S. and Russian crew to make an emergency landing. A second one was quickly put together for the subsequent mission.
The parent company of 3D Bioprinting Solutions is INVITRO, the largest private medical company in Russia. Founded in 1995 by Aleksandr Ostrovsky, it has 8 laboratories and over 1000 medical offices in eastern Europe, but is primarily based in Skolkovo, a high technology business area in Moscow. Bioprinting Solutions made headlines in 2015 when it printed and transplanted a functioning mouse thyroid gland. The experiment performed aboard the ISS with Organaut was a modified version of their prior work.
Unlike NASA, Roscosmos does not generally partner with private companies for its research endeavors. In an effort to inspire Russian students to enter STEM fields within their country, the agency sought to spotlight the developing bioprinting industry by using the Organaut. The successful partnership with 3D Bioprinting Solutions has now motivated the agency to continue partnering with private companies in the future. The company itself also sees advantages to collaborations of its own with other Skolkova-area manufacturers. “We have companies that are making satellite platforms…it is possible to conduct a similar experiment amid microgravity on small spacecraft [like satellites]…smaller and cheaper,” noted Ivan Kosenkov, 3D Bioprinting Solutions’ project manager.
Organaut’s printed tissues were returned to Earth with the Soyuz MS-09 spacecraft on December 20th, and the results of the experiment are expected to be published at the end of January 2019. In February, NASA plans to send a bioprinter capable of producing beating heart tissue to the ISS. Named the 3D BioFabrication Facility (BFF), the machine was developed through a partnership with two companies well-established in 3D printing and on-orbit hardware, nScrypt and Techshot. Since the thickness of heart tissue is difficult to build under gravity without structural assistance that could impede functionality, the companies developed the BFF with the hypothesis that microgravity would overcome this limitation. Thus far, the concept has been proven during parabolic flight tests, i.e., aboard the “Vomit Comet” airplane that performs multiple parabolic maneuvers in an airliner to create 20-30 seconds of weightlessness each.
Tesla stock (NASDAQ: TSLA) endured one of its sharpest single-day declines in years on July 23, tumbling approximately 14.5 percent and closing near $320 after opening the session around $374. The drop erased more than $140 billion in market value amid heavy trading volume and left the shares at multi-week lows.
The sell-off followed the company’s second-quarter 2026 results, released the previous evening. Tesla reported record revenue of $28.2 billion, up 26 percent year over year, driven by a Q2-record 480,126 vehicle deliveries. Energy storage deployments also rose strongly.
Tesla (TSLA) Q2 2026 earnings results: miss on EPS, beat on revenue
Yet profitability disappointed sharply. Operating income fell 57 percent to $398 million, compressing the operating margin to just 1.4 percent. Non-GAAP earnings per share came in at $0.33, well below the roughly $0.53 analysts had expected. Free cash flow turned negative by $1.1 billion as capital expenditures surged 142 percent to $5.8 billion, largely tied to accelerated spending on artificial intelligence, robotics, and autonomous systems.
The losses on capex were expected, as Tesla said it would be spending heavily in 2026.
Investors also reacted to lingering uncertainty surrounding key product timelines. During the Earnings Call, management reiterated ambitions for Robotaxi deployment and the Optimus humanoid robot, but offered limited new concrete milestones, renewing questions about execution pace that have long accompanied Tesla’s ambitious roadmap.
The magnitude of the decline places it among Tesla’s more severe one-day percentage losses since its 2010 initial public offering. Historically, the two largest single-day drops (split-adjusted) remain September 8, 2020, when shares fell 21.1 percent amid broader market volatility and valuation concerns, and January 13, 2012, with a 19.3 percent plunge during the company’s early growth struggles.
Other notable declines include an 18.6 percent drop on March 16, 2020, at the onset of pandemic-related market turmoil. Thursday’s move ranks roughly ninth on the all-time list but stands out as the steepest in more than a year.
Despite the short-term pain, Tesla’s long-term trajectory has repeatedly recovered from such volatility. The latest results underscore both the strength of its core automotive and energy businesses and the near-term costs of heavy investment in next-generation technologies.
Elon Musk clapped back at France’s decision to withhold the approval for Tesla’s Full Self-Driving (FSD) Supervised system, projecting a clear and blunt message to French Transport Minister Phillippe Tabarot, after he publicly rejected the technology in its current form.
Tabarot outlines several concerns with Tesla Full Self-Driving in a detailed video statement, where he said, “The safety trade-offs are not yet sufficient to authorize it as it currently stands,” he said. He emphasized that FSD is not a true self-driving system and that the driver remains fully responsible.
Key issues Tabarot also brought up included allowing speeding when surrounding traffic exceeds limits and what he believes are insufficient guarantees of driver attention during complex urban maneuvers such as lane changes, intersections, and roundabouts.
Delaying the approval of FSD in France will cost lives
— Elon Musk (@elonmusk) July 22, 2026
While acknowledging technological progress and France’s support for autonomous innovation, Tabarot stressed that deployment must prioritize road safety. He noted ongoing technical discussions with Tesla, the Netherlands, and other European partners, with further ecosystem meetings planned for the fall.
Musk’s rebuke highlights the human cost of regulatory caution. Tesla’s latest safety reports provide compelling data supporting accelerated adoption. In the most recent 12-month period, vehicles using FSD (Supervised) recorded one major collision per approximately 5.1 million miles driven, dramatically better than the U.S. national average of one crash per 698,000 miles.
Even Tesla vehicles driven manually with active safety features outperform the average by a wide margin. These figures come from billions of real-world miles of telemetry, showing FSD vehicles involved in far fewer incidents than both manual Teslas and the broader U.S. fleet.
Critics argue Tesla’s comparisons require careful scrutiny regarding reporting thresholds and fleet demographics, yet the data consistently positions FSD as a potential lifesaver. With road fatalities remaining a leading cause of death worldwide, Musk contends that proven safer technology should not face prolonged bureaucratic hurdles.
France’s measured approach reflects the broader European regulatory caution, which many, especially Musk, have been critical of in the past. However, as autonomous systems from Tesla and competitors like Waymo demonstrate superior safety in independent studies, pressure is mounting for harmonized approvals.
Musk’s warning carries the belief that every month of delay may equate to avoidable tragedies on European roads.
In a striking revelation that underscores the lucrative crossover between Big Tech and space exploration, Alphabet Inc., Google’s parent company, disclosed a massive $94.1 billion equity stake in SpaceX following the rocket company’s blockbuster initial public offering earlier this year.
The disclosure came in Alphabet’s quarterly filing, marking the first time the long-held private investment has been publicly valued at market prices. Google was an early backer, investing alongside Fidelity in 2015 with roughly $500-900 million at a time when SpaceX was valued around $12 billion.
That bet has delivered extraordinary returns, roughly a hundredfold, transforming a strategic play on satellite internet and launch capabilities into one of Alphabet’s largest assets.
Google, $GOOGL, has said they hold $94 billion in SpaceX, $SPCX, shares after IPO.
— unusual_whales (@unusual_whales) July 23, 2026
Of the total holding, approximately $80 billion remains subject to short-term post-IPO lockup restrictions, preventing near-term sales. An additional $14.1 billion faces longer-term restrictions, extending into the third quarter of 2027. This structure limits immediate liquidity but protects against market volatility as SpaceX transitions into public trading.
The SpaceX position contributed significantly to gains in Alphabet’s broader investment portfolio, which also includes a major stake in AI leader Anthropic. Combined, these holdings helped drive nearly $100 billion in investment gains during the second quarter, providing a substantial boost to net income amid ongoing AI spending pressures.
Analysts view the disclosure as validation of Alphabet’s venture strategy beyond its core search and cloud businesses. The investment aligns with deeper ties, including reported multi-billion-dollar deals for AI computing capacity on SpaceX infrastructure. As SpaceX advances Starship flights, Starlink expansion, and ambitious Mars goals under Elon Musk, Google’s stake positions it to benefit from the commercialization of space.
For Alphabet, the windfall highlights how patient, forward-looking bets in transformative sectors can yield outsized rewards. While lockups temper short-term impact, the holding cements SpaceX as a cornerstone of Alphabet’s diversified portfolio in an era where aerospace, AI, and connectivity increasingly intersect. Investors will watch closely as restrictions lift and SpaceX’s public performance unfolds.
Tesla stock tumbles after earnings, one of its sharpest single-day declines
Elon Musk is not happy about this Tesla Full Self-Driving approval delay
